Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome

Endocrine

Volumn 47, Issue 2, 2014, Pages 631-638

  Livadas, Sarantis ^a   Pappas, Christos ^a   Karachalios, Athanasios ^a   Marinakis, Evangelos ^a   Tolia, Nikoleta ^a   Drakou, Maria ^a   Kaldrymides, Philippos ^a   Panidis, Dimitrios ^b   Diamanti Kandarakis, Evanthia ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Hyperandrogenemia; Ovarian volume; Polycystic ovary syndrome; Testosterone

Indexed keywords

ANDROSTENEDIONE; FOLLITROPIN; GLUCOSE; LUTEINIZING HORMONE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; ANDROGEN;

ADULT; ANDROGEN BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BODY MASS; CAUCASIAN; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEHYDROEPIANDROSTERONE SULFATE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; FOLLITROPIN BLOOD LEVEL; FREE ANDROGEN INDEX; GLUCOSE BLOOD LEVEL; GREEK (PEOPLE); HUMAN; HYPERANDROGENISM; LEAN BODY WEIGHT; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; ORGAN SIZE; OVARY POLYCYSTIC DISEASE; OVARY VOLUME; PHENOTYPE; PREVALENCE; TESTOSTERONE BLOOD LEVEL; BLOOD; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

ADULT; ANDROGENS; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPERANDROGENISM; LUTEINIZING HORMONE; POLYCYSTIC OVARY SYNDROME; PREVALENCE; SEX HORMONE-BINDING GLOBULIN; YOUNG ADULT;

EID: 84911004398     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0200-7     Document Type: Article

References (30)

1. E. Diamanti-Kandarakis, Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev. Mol. Med. 3010, e3 (2008)
2. E. Diamanti-Kandarakis, A. Dunaif, Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr. Rev. 33, 981–1030 (2012)
3. E. Kandaraki, C. Christakou, E. Diamanti-Kandarakis, Metabolic syndrome and polycystic ovary syndrome… and vice versa. Arq. Bras. Endocrinol. Metabol. 53, 227–237 (2009)
4. E. Diamanti-Kandarakis, D. Panidis, Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin. Endocrinol. (Oxf.) 67, 735–742 (2007)
5. E. Diamanti-Kandarakis, C. Christakou, E. Marinakis, Phenotypes and environmental factors: their influence in PCOS. Curr. Pharm. Des. 18, 270–282 (2012)
6. S.F. Witchel, S.E. Recabarren, F. González, E. Diamanti-Kandarakis, K.I. Cheang, A.J. Duleba, R.S. Legro, R. Homburg, R. Pasquali, R.A. Lobo, C.C. Zouboulis, F. Kelestimur, F. Fruzzetti, W. Futterweit, R.J. Norman, D.H. Abbott, Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. Endocrine 42, 526–534 (2012)
7. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Fertil. Steril. 81, 19–25 (2004)
8. M.A. Lawson, S. Jain, S. Sun, K. Patel, P.J. Malcolm, R.J. Chang, Evidence for insulin suppression of baseline luteinizing hormone in women with polycystic ovarian syndrome and normal women. J. Clin. Endocrinol. Metab. 93, 2089–2096 (2008)
9. T.D. Pache, F.H. de Jong, W.C. Hop, B.C. Fauser, Association between ovarian changes assessed by transvaginal sonography and clinical and endocrine signs of the polycystic ovary syndrome. Fertil. Steril. 59, 544–549 (1993)
10. A.A. Kyei-Mensah, S. LinTan, J. Zaidi, H.S. Jacobs, Relationship of ovarian stromal volume to serum androgen concentrations in patients with polycystic ovary syndrome. Hum. Reprod. 13, 1437–1441 (1998)
11. Z. Puzigaća, G.M. Prelević, Z. Stretenović, L. Balint-Perić, Ovarian enlargement as a possible marker of androgen activity in polycystic ovary syndrome. Gynecol. Endocrinol. 5, 167–174 (1991)
12. R. Pasquali, A. Gambineri, C. Cavazza, D. Ibarra Gasparini, W. Ciampaglia, G.E. Cognigni, U. Pagotto, Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur. J. Endocrinol. 164, 53–60 (2011)
13. P. Moghetti, R. Castello, C. Negri, F. Tosi, F. Perrone, M. Caputo, E. Zanolin, M. Muggeo, Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo controlled 6-month trial, followed by open long-term. J. Clin. Endocrinol. Metab. 85, 139–146 (2000)
14. N. Köşüş, A. Köşüş, Z. Kamalak, D. Hızlı, N.Ö. Turhan, Impact of adrenal versus ovarian androgen ratio on signs and symptoms of polycystic ovarian syndrome. Gynecol. Endocrinol. 28, 611–614 (2012)
15. K. Brennan, A. Huang, R. Azziz, Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. Fertil. Steril. 91, 1848–1852 (2009)
16. A. Dagre, J. Lekakis, C. Mihas, A. Protogerou, L. Thalassinou, D. Tryfonopoulos, G. Douridas, C. Papamichael, M. Alevizaki, Association of dehydroepiandrosterone-sulfate with endothelial function in young women with polycystic ovary syndrome. Eur. J. Endocrinol. 154, 883–890 (2006)
17. D. Panidis, K. Tziomalos, E. Papadakis, C. Vosnakis, P. Chatzis, I. Katsikis, Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility. Endocrine 44, 583–590 (2013)
18. A. Huang, K. Brennan, R. Azziz, Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the NIH 1990 criteria. Fertil. Steril. 93, 1938–1941 (2010)
19. R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, W. Futterweit, O.E. Janssen, R.S. Legro, R.J. Norman, A.E. Taylor, S.F. Witchel, Task force on the phenotype of the polycystic ovary syndrome of the androgen excess and PCOS Society. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. Fertil. Steril. 9, 456–488 (2009)
20. L. Gabrielli, E.M. Aquino, Polycystic ovary syndrome in Salvador, Brazil: a prevalence study in primary healthcare. Reprod. Biol. Endocrinol. 10, 96 (2012)
21. E. Diamanti-Kandarakis, J. Papailiou, S. Palimeri, Hyperandrogenemia: pathophysiology and its role in ovulatory dysfunction in PCOS. Pediatr. Endocrinol. Rev. 3, 198–204 (2006)
22. S.K. Blank, C.R. McCartney, J.C. Marshall, The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Hum. Reprod. Update 12, 351–361 (2006)
23. A.E. Taylor, B. McCourt, K.A. Martin, E.J. Anderson, J.M. Adams, D. Schoenfeld, J.E. Hall, Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82, 2248–2256 (1997)
24. C.M. Solorzano, J.P. Beller, M.Y. Abshire, J.S. Collins, C.R. McCartney, J.C. Marshall, Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids 77, 332–337 (2012)
25. A.J. Jakimiuk, S.R. Weitsman, A. Navab, D.A. Magoffin, Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. J. Clin. Endocrinol. Metab. 86, 1318–1323 (2001)
26. V.L. Nelson, R.S. Legro, J.M. McAllister, Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol. Endocrinol. 13, 946–957 (1999)
27. R.L. Rosenfield, B. Bordini, Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity. Brain Res. 1364, 186–197 (2010)
28. V. Toscano, R. Balducci, P. Bianchi, R. Guglielmi, A. Mangiantini, F. Sciarra, Steroidal and non-steroidal factors in plasma sex hormone binding globulin regulation. J. Steroid Biochem. Mol. Biol. 43, 431–437 (1992)
29. M.G. Forest, A. Lecoq, M. David, M. Pugeat, Effects of human chorionic gonadotropin, androgens, adrenocorticotropin hormone, dexamethasone and hyperprolactinemia on plasma sex steroid-binding protein. Ann. N. Y. Acad. Sci. 538, 214–234 (1988)
30. F. González, C.L. Sia, F.Z. Stanczyk, H.E. Blair, M.E. Krupa, Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome. Endocrine 42, 726–735 (2012)